ACAD logo

ACAD Acadia Pharmaceuticals Inc

$19.80
$0.31
(1.54%)
Today
50

Neutral Sentiment

How do you feel about ACAD?

Loading...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADPR NewswireNEW YORK, Oct. 1, 2026NEW YORK, Oct. 1, 2026 /PRNewswire...
PR Newswire
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
Zacks
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled Methods and Compositions for Treatment of Rett Syndrome. The Notice of Allowance indicates that...
Business Wire
ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets
Acadia's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation.
Stocktwits
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
Zacks
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%
Citi’s Yigal Nochomovitz trimmed his price target to $33 from $40 and kept a Buy rating following the company’s update.
Stocktwits
Acadia Drug Misses Primary Goal in Alzheimer's Related Psychosis
Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer's psychosis and plans to move into Phase 3.read more...
Benzinga
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimers Disease Psychosis (ADP)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimers disease psychosis (ADP). For the...
Business Wire
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks